



CSE: CURE | OTCQB: BICTF
www.biocuretech.com

Biocure Technology Inc. is a publicly traded biotechnology company developing and commercializing biosimilar pharmaceuticals and other recombinant proteins. Biocure's mission is to continue to advance the research and development of our products in the most ethical and cost-effective manner as possible.

OUR PRODUCTS

Biopharmaceuticals

Biocure started conducting pre-clinical trials of its biosimilar candidates last year, and now has multiple product studies underway, including:

- **Interferon Beta 1b** (Multiple Sclerosis treatment). **This is the company's most advanced product.** The pre-clinical trial shall be complete by the end of Q1 2019; clinical trial shall start in Q3 2019.
- **PEG-Filgrastim** (Anti-cancer treatment; Pre-clinical trial stage.)
- **Ranibizumab** (Macular degeneration treatment; Pre-clinical trial stage.)

At this pre-clinical trial phase, the company has the technology and capability for commercial mass production.

CAR-T Cell Therapy (Immune-therapy for cancer)

CAR-T cell therapy is one of the most promising targeted immune-therapies and has received extensive attention which has resulted in multiple applications.

BIOCURE has established pre-clinical and clinical designs of 2nd generation CAR-T cell, standard protocol for conditioning and infusion, better control of complications and combination with other therapeutic options.

A pre-clinical study shall be complete by the end of Q3 2018 and a clinical study shall start in Q2 2019.

Other Vaccines & Products

- Foot and Mouth Disease Vaccine
- Recombinant human growth factor for hair growth and skin regeneration



Share Structure (As of June 7, 2018)

Issued shares	96,473,301
Options	5,105,000
Warrants	3,790,680
Fully Diluted	105,368,981
Share Price	0.55
Market Cap	58 Million
Held by Insiders	28%

Investor Information

300 - 1055 West Hastings St.
Vancouver BC V6E 2E9

info@biocuretech.com

+1 (604) 609-7146

A highly-skilled team of researchers combined with professional public company management.

Sang Mok Lee, Ph.D.
President, CEO & Director

Konstantin Lichtenwald
CFO & Director

Marco Nonni
Director

Sang Goo (Collin) Kim
Director

Jae Soo Shin, Ph.D.
Managing Director,
Il-Yang Pharm Co. Ltd. Korea
Advisor

Heon Ju Lee, Ph.D.
Advisor

Hyun Soo Lee, Ph.D.
Advisor

